Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents
Public ClinicalTrials.gov record NCT00224042. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Being Treated With Erythropoietic Therapy
Study identification
- NCT ID
- NCT00224042
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Interventions
- Sodium Ferric Gluconate complex in sucrose Drug
- Ferrous sulfate tablets Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2003
- Primary completion
- Apr 30, 2005
- Completion
- Not listed
- Last update posted
- Mar 28, 2012
Started 2003
United States locations
- U.S. sites
- 23
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Palo Alto | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Hines | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Springfield | Massachusetts | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Detroit | New York | — | — |
| Not listed | Mineola | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | The Bronx | New York | — | — |
| Not listed | Chapel Hill | North Carolina | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Charlotte | South Carolina | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Fairfax | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00224042, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2012 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00224042 live on ClinicalTrials.gov.